drugset / Trial / NCT04777643

Sex Differences in Neural Response to Cannabidiol

NCT04777643

Phase 0 Completed 19 enrolled Yale University
RandomizedCrossoverTriple-blindBasic science

Summary

This is a randomized, double-blind, within-subjects, cross-over design to assess neural changes following a single dose of cannabidiol (CBD) (600mg) versus placebo among healthy female volunteers.

Timeline

Start
2022-06-07
Primary completion
2023-04-27
Completion
2023-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 600 mg Oral

Indications

No indication recorded.